Printed from the IBC Life Sciences Web site on May 22, 2012 5:20 AM ET.
Page location: http://www.ibclifesciences.com/BPIChina/overview.xml
August 21-22, 2012 · Grand Hyatt Shanghai · Shanghai, China
Register by May 25 to take advantge of early registration discounts.
Continuous Bioprocessing for Production of Recombinant Proteins and Monoclonal Antibodies
Weichang Zhou, Ph.D., Senior Director, Commercial Cell Culture Development, Genzyme, a Sanofi Company
Comparability vs Similarity for Biosimilarity Assessment - Challenges and Opportunities in US FDA Biosimilar Guidance
Earl Dye, Ph.D., Director, Technical Regulatory Policy & Strategy, Genentech Inc.
Opportunities and Challenges for the Development of Biosimilar Monoclonal Antibodies in Europe
Sandy Eisen, M.D., MA FRCS, Dip Pharm Med, Chief Medical Officer, Frontline Pharma Consulting Ltd., United Kingdom
At IBC's 4th Annual BioProcess International™ China event, the goal is to bring China and the rest of the world together to explore the missing gaps in China's development, and to help bring China up-to-speed on critical areas such as cell line engineering, media development, analytical characterization strategies to establish similarity between a biosimilar and its originator drug, as well as design of multi-product facilities and implementation of single-use systems.
Bringing together global leaders to provide you with proven scientific and technical strategies and innovations on:
Delivering you so much MORE in just 2 days...
Don't miss this opportunity to witness and partake in China's phenomenal growth! Get insider information and proven strategies to help increase your yield, improve your quality while ensuring efficiency of production and reducing manufacturing cost.
International companies:
This is your chance to meet and network with domestic Chinese/Asian drug developers, contract manufacturers and understand where they are in the area of processing capabilities, as well as find potential business partners and collaborators to develop biosimilars, biobetters or novel biologics.
China-based companies:
This is your opportunity to learn technical know-how and practical solutions from the experienced scientists and engineers from around the world, as well as hear how to trouble-shoot problems and avoid pitfalls in the quest for higher yield and better quality.